FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911476543> ?p ?o ?g. }

• W2911476543 abstract "634 Background: Chemotherapy in relapsed colon cancer patients (pts) treated with oxaliplatin as adjuvant chemotherapy is under debate. REACT study aimed to investigate the efficacy of re-introducing FOLFOX or XELOX ± bevacizumab therapy for recurrent colorectal cancer pts after adjuvant chemotherapy including oxaliplatin. Methods: Pts with past history of adjuvant chemotherapy including oxaliplatin (FOLFOX, XELOX or SOX) with a cumulative dose of more than 400 mg/m 2 , and recurrence observed by imaging after more than 6 months post adjuvant chemotherapy participated in this trial. Primary endpoints were response rate (RR) and disease control rate (DCR). Key secondary endpoints were progression-free survival (PFS), time to treatment failure (TTF), overall survival (OS) and safety. Results: A total of 31 pts were enrolled between Oct 2012 and Oct 2016. Of 29 eligible pts, 7 received FOLFOX ± bevacizumab, and 22 received XELOX ± bevacizumab. 28 of the pts received bevacizumab. The RR was 66.7% (95% CI, 46.0-83.5) and the DCR was 88.9% (95% CI, 70.8-97.6). The RR for oxaliplatin free-interval was 100.0% (n = 4, 95% CI, 39.8-100.0) in 6 to 12 months, 60.9% (n = 25, 95% CI, 38.5-80.3%) over 12 month, respectively. Median PFS, TTF and OS were 10.9 months (95% CI, 7.0-19.0), 6.3 months (95% CI, 2.8-8.0) and 29.1 months (95% CI, 20.3-53.3). The most common grade 3 or 4 adverse event was hypertension (19.4%). Grade 3 or worse peripheral sensory neuropathy developed only two pts (6.5%). Allergic reactions occurred in 12.9% of the pts, with one (3.2%) grade 3 episode. There were no other severe treatment-related adverse events. Conclusions: Re-introduction of oxaliplatin was feasible and achieved high RR or DCR in after more than 6 months post adjuvant chemotherapy including oxaliplatin. Clinical trial information: UMIN000006523." @default.
• W2911476543 created "2019-02-21" @default.
• W2911476543 creator A5002809808 @default.
• W2911476543 creator A5003648443 @default.
• W2911476543 creator A5031011136 @default.
• W2911476543 creator A5033008284 @default.
• W2911476543 creator A5033139611 @default.
• W2911476543 creator A5034244777 @default.
• W2911476543 creator A5040676201 @default.
• W2911476543 creator A5051765795 @default.
• W2911476543 creator A5058315816 @default.
• W2911476543 creator A5058524907 @default.
• W2911476543 creator A5062868734 @default.
• W2911476543 creator A5063817865 @default.
• W2911476543 creator A5067750848 @default.
• W2911476543 creator A5070941567 @default.
• W2911476543 creator A5084398419 @default.
• W2911476543 date "2019-02-01" @default.
• W2911476543 modified "2023-10-02" @default.
• W2911476543 title "Evaluation of the re-introducing FOLFOX or XELOX ± bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)." @default.
• W2911476543 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.634" @default.
• W2911476543 hasPublicationYear "2019" @default.
• W2911476543 type Work @default.
• W2911476543 sameAs 2911476543 @default.
• W2911476543 citedByCount "0" @default.
• W2911476543 crossrefType "journal-article" @default.
• W2911476543 hasAuthorship W2911476543A5002809808 @default.
• W2911476543 hasAuthorship W2911476543A5003648443 @default.
• W2911476543 hasAuthorship W2911476543A5031011136 @default.
• W2911476543 hasAuthorship W2911476543A5033008284 @default.
• W2911476543 hasAuthorship W2911476543A5033139611 @default.
• W2911476543 hasAuthorship W2911476543A5034244777 @default.
• W2911476543 hasAuthorship W2911476543A5040676201 @default.
• W2911476543 hasAuthorship W2911476543A5051765795 @default.
• W2911476543 hasAuthorship W2911476543A5058315816 @default.
• W2911476543 hasAuthorship W2911476543A5058524907 @default.
• W2911476543 hasAuthorship W2911476543A5062868734 @default.
• W2911476543 hasAuthorship W2911476543A5063817865 @default.
• W2911476543 hasAuthorship W2911476543A5067750848 @default.
• W2911476543 hasAuthorship W2911476543A5070941567 @default.
• W2911476543 hasAuthorship W2911476543A5084398419 @default.
• W2911476543 hasConcept C121608353 @default.
• W2911476543 hasConcept C126322002 @default.
• W2911476543 hasConcept C143998085 @default.
• W2911476543 hasConcept C2776694085 @default.
• W2911476543 hasConcept C2777802072 @default.
• W2911476543 hasConcept C2777863537 @default.
• W2911476543 hasConcept C2777909004 @default.
• W2911476543 hasConcept C2778260052 @default.
• W2911476543 hasConcept C2780456651 @default.
• W2911476543 hasConcept C2780962732 @default.
• W2911476543 hasConcept C3018227240 @default.
• W2911476543 hasConcept C526805850 @default.
• W2911476543 hasConcept C530470458 @default.
• W2911476543 hasConcept C71924100 @default.
• W2911476543 hasConceptScore W2911476543C121608353 @default.
• W2911476543 hasConceptScore W2911476543C126322002 @default.
• W2911476543 hasConceptScore W2911476543C143998085 @default.
• W2911476543 hasConceptScore W2911476543C2776694085 @default.
• W2911476543 hasConceptScore W2911476543C2777802072 @default.
• W2911476543 hasConceptScore W2911476543C2777863537 @default.
• W2911476543 hasConceptScore W2911476543C2777909004 @default.
• W2911476543 hasConceptScore W2911476543C2778260052 @default.
• W2911476543 hasConceptScore W2911476543C2780456651 @default.
• W2911476543 hasConceptScore W2911476543C2780962732 @default.
• W2911476543 hasConceptScore W2911476543C3018227240 @default.
• W2911476543 hasConceptScore W2911476543C526805850 @default.
• W2911476543 hasConceptScore W2911476543C530470458 @default.
• W2911476543 hasConceptScore W2911476543C71924100 @default.
• W2911476543 hasLocation W29114765431 @default.
• W2911476543 hasOpenAccess W2911476543 @default.
• W2911476543 hasPrimaryLocation W29114765431 @default.
• W2911476543 isParatext "false" @default.
• W2911476543 isRetracted "false" @default.
• W2911476543 magId "2911476543" @default.
• W2911476543 workType "article" @default.